瑞戈非尼联合PD-1抗体治疗肝癌的效果研究

Study on the Effect of Regorafenib Combined with PD-1 Antibody in the Treatment of Liver Cancer

目的:探讨瑞戈非尼联合PD-1抗体在抑制肝癌患者癌细胞生长过程中的临床应用价值。方法:选择2019年7月—2020年7月在永城市人民医院接受治疗的肝癌患者120例作为研究对象,按照随机数字表法分为观察组和对照组,每组60例。对照组采用瑞戈非尼治疗,观察组在对照组治疗基础上联合PD-1治疗。比较两组临床疗效、不良反应以及免疫功能指标。结果:观察组治疗总有效率为78.33%,高于对照组的63.33%(P<0.05);观察组不良反应发生率为11.67%,低于对照组的21.67%(P<0.05)。治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)高于治疗前,CD8^(+)低于治疗前,且观察组CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。结论:瑞戈非尼结合PD-1抗体在抑制肝癌患者癌细胞生长中有显著的临床疗效,不仅能有效改善患者的免疫功能,还能减少患者的不良反应。

Objective:To investigate the clinical application value of regorafenib combined with PD-1 antibody in inhibiting the growth of cancer cells in patients with liver cancer.Methods:A total of 120 patients with liver cancer who were treated in our hospital from July 2019 to July 2020 were selected as the research objects.According to the random number table method,they were divided into observation group and control group,with 60 patients in each group.The control group was treated with regorafenib,and the observation group was treated with PD-1 on the basis of the control group.The clinical efficacy,adverse reactions and immune function indexes of the two groups were compared.Results:The total effective rate of treatment in the observation group was 78.33%,which was higher than 63.33%in the control group(P<0.05).The incidence of adverse reactions in the observation group was 11.67%,which was lower than 21.67%in the control group(P<0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before treatment,CD8^(+)was lower than that before treatment,and CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,CD8^(+)was lower than that in the control group(P<0.05).Conclusion:Regorafenib combined with PD-1 antibody has a significant clinical effect in inhibiting the growth of cancer cells in patients with liver cancer.It can not only effectively improve the immune function of patients,but also reduce the adverse reactions of patients.